Magazine Article | November 1, 2023

Companies To Watch: Freya Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Enlivening the longtime lonely space of reproductive health, starting with a new focus on the vaginal microbiome

Freya Biosciences is a Danish company developing new vaginal microbial immunotherapies, with its lead candidate, coded FB101, about to enter Phase 2 to improve success of in vitro fertilization (IVF). FB101 targets the imbalance among constituents of the vaginal microbiome that causes local immune dysregulation and inflammation in the female reproductive tract. Other candidates are still in early discovery and preclinical development for a range of reproductive-health indications. The overall goal is to restore a normal vaginal microbiome and eliminate conditions that hinder or block women’s reproductive functions and undermine treatments such as in vitro fertilization (IVF).

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader